Navigation Links
SynCardia's Companion 2 Driver Named a Finalist in the Medical Design Excellence Awards
Date:4/4/2013

TUCSON, Ariz., April 4, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that its Companion 2 (C2) Driver System, which powers the SynCardia temporary Total Artificial Heart in the hospital, has been selected as one of four finalists in the Critical-Care and Emergency Medicine Products category of the 15th Annual Medical Design Excellence Awards (MDEA). The winners will be announced on June 19 in Philadelphia.

(Photo: http://photos.prnewswire.com/prnh/20130404/LA88555)

"Prior to the development of the C2 Driver, the only FDA-approved driver for powering the Total Artificial Heart in the hospital was the 418-pound 'Big Blue' driver," said Michael Garippa , SynCardia Chairman/CEO/President. "Although Big Blue is extremely reliable, its size and weight reduces patient mobility and there are only 36 available worldwide. The state-of-the-art C2 Driver, which we manufacture and have more than 90 units at SynCardia Certified Centers, is both robust and mobile, supporting very sick patients of all sizes in the operating room and in the hospital during recovery and ambulation."

For the Total Artificial Heart implant, the C2 Driver is docked in the Hospital Cart. Featuring sturdy support handles and locking casters, the Hospital Cart assists patients in standing and walking during their early recovery. Once the patient is out of bed and ambulatory, the C2 Driver can be docked in the Driver Caddy, which provides patients with greater mobility in the hospital and on hospital grounds.

Once stable, patients who are eligible can be switched to the 13.5-pound Freedom® portable driver, the world's first wearable power supply for the SynCardia Total Artificial Heart. Patients who meet discharge criteria can then leave the hospital and wait for a matching donor heart at home and in their communities. The Freedom portable driver was selected by MDEA as the Bronze Winner in the Critical Care and Emergency Medicine Products category in 2012.

The Medical Design Excellence Awards are the industry's premier design awards competition and is the only awards program exclusively recognizing contributions and advances in the design of medical products. Entries were evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability to overcome design and engineering challenges to meet clinical objectives.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. To see the full list of SynCardia Awards & Recognition go to: http://www.syncardia.com/SynCardia/syncardia-awards-and-recognition.html.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019 
Follow SynCardia on Twitter – http://twitter.com/SynCardia 
Connect with SynCardia on LinkedIn - http://www.linkedin.com/company/syncardia-systems-inc.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
2. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
3. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
4. The Complete Guide to Companion Diagnostics: Market Environment Products and Companies
5. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
6. Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes
7. Eutropics Pharmaceuticals signs $1.5M NCI/SBIR contract to develop companion diagnostic for guiding Multiple Myeloma treatments
8. Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
9. Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
10. Companion Diagnostics and Personalized Medicine Market Report 2012: Twease.org
11. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... Opportunities for Leading Companies – our new study reveals ... discusses issues and events affecting the Alzheimer,s disease therapeutics ... to answer these key questions: - How is the ...
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... , ... Source Vitál Apothecary, a skin and body care company dedicated to ... had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference ... the nutritional, sports and health industries a chance to meet in private sessions with ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an ... life, announced it had a successful January ECRM Trade Show in Hilton Head, SC. ... States, which allows it to provide its products to all clients at reasonable prices. ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
Breaking Medicine News(10 mins):